Last reviewed · How we verify

NCT06250829: Pre-PLaN

Model to Predict pCR and IrAEs in Early Stage Non-small Cell Lung Cancer

Status unknown Last updated 9 February 2024
What this trial tests

trial testing Observational in Non-small Cell Lung Cancer Stage IB (Resectable) in 60 participants. Status unknown.

Timeline
12 October 2023
Primary endpoint
30 October 2024
30 May 2025

Quick facts

Lead sponsorLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment60
Start date12 October 2023
Primary completion30 October 2024
Estimated completion30 May 2025
Sites1 location across Canada

Drugs / interventions tested

Conditions studied

Sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Who can join

18 and older, any sex, with Non-small Cell Lung Cancer Stage IB (Resectable) or Non-small Cell Lung Cancer Stage II (Resectable). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Lung cancer is the chief cause of cancer death. The new standard-of-care (SOC) in operable lung cancer combines chemotherapy and an immune-stimulating drug before the surgery (neoadjuvant approach). This results in a large increase in complete cancer clearance rates compared to chemotherapy alone (±30% with combination vs ±4% with chemotherapy alone), leading to much better long-term survival and probably many more cures. However, most still don't achieve complete clearance, and a few have increases in, or spread of, their tumors while on treatment. Therefore, we need to understand why some patients benefit (responders) and others don't benefit (non-responders) on an immunotherapy-based treatment. Also, some patients unpredictably develop severe immune-type side effects related to the immunotherapy drug, although such side effects may be associated with improved anti-cancer effects. In short, the same treatment can result in complete cancer clearance in one patient, and in a worst-case scenario may result in severe toxicity or fail to control spread/growth thus precluding surgery. The immune system obviously plays a key role in both benefit and harm, yet most of the research in this field has focused only on the cancer. We plan an in-depth study in 60 patients, focusing on the cancer as well as the patient's immune system, pre-surgery. This will enable us to identify factors predicting complete cancer clearance, and the occurrence of immune-type side effects. Using highly sophisticated resources available to us here in London, we will develop predictive models enabling better patient management (including possible avoidance of surgery), and identification of key biological differences between major responders and non-responders, to highlight important new targets for the development of even newer and better therapies.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. An Updated Review of Management of Resectable Stage III NSCLC in the Era of Neoadjuvant Immunotherapy.
    Verma S, Breadner D, Mittal A, Palma DA, et al · · 2024 · cited 10× · PMID 38610980 · DOI 10.3390/cancers16071302

Verify or expand the search:

Other trials of Observational

Trials testing the same drug.

Other London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06250829.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing